Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure–activity relationship insights and evolution perspectives
The viral main protease is one of the most attractive targets among all key enzymes involved
in the SARS-CoV-2 life cycle. Covalent inhibition of the cysteine145 of SARS-CoV-2 MPRO …
in the SARS-CoV-2 life cycle. Covalent inhibition of the cysteine145 of SARS-CoV-2 MPRO …
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …
Recent advances in SARS-CoV-2 main protease inhibitors: from nirmatrelvir to future perspectives
A Citarella, A Dimasi, D Moi, D Passarella, A Scala… - Biomolecules, 2023 - mdpi.com
The main protease (Mpro) plays a pivotal role in the replication of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target …
syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target …
Targeted Protein Degradation through Recruitment of the CUL4 Complex Adaptor Protein DDB1
M Meyers, S Cismoski, A Panidapu… - ACS chemical …, 2024 - ACS Publications
Targeted protein degradation has arisen as a powerful therapeutic modality for eliminating
proteins. Thus far, most heterobifunctional proteolysis targeting chimeras (PROTACs) have …
proteins. Thus far, most heterobifunctional proteolysis targeting chimeras (PROTACs) have …
SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies
C Fischer, JR Feys - Future Pharmacology, 2023 - mdpi.com
While the COVID-19 pandemic seems to be on its decline, the unclear impacts of long-
COVID cases, breakthrough infections in immunocompromised individuals, vaccine …
COVID cases, breakthrough infections in immunocompromised individuals, vaccine …
Large library docking for novel SARS‐CoV‐2 main protease non‐covalent and covalent inhibitors
Antiviral therapeutics to treat SARS‐CoV‐2 are needed to diminish the morbidity of the
ongoing COVID‐19 pandemic. A well‐precedented drug target is the main viral protease …
ongoing COVID‐19 pandemic. A well‐precedented drug target is the main viral protease …
Molecular docking via quantum approximate optimization algorithm
Molecular docking plays a pivotal role in drug discovery and precision medicine, furnishing
insights into protein functionalities and fostering the development of therapeutics. Here, we …
insights into protein functionalities and fostering the development of therapeutics. Here, we …
On the origins of SARS-CoV-2 main protease inhibitors
YL Janin - RSC Medicinal Chemistry, 2024 - pubs.rsc.org
In order to address the world-wide health challenge caused by the COVID-19 pandemic, the
3CL protease/SARS-CoV-2 main protease (SARS-CoV-2-Mpro) coded by its nsp5 gene …
3CL protease/SARS-CoV-2 main protease (SARS-CoV-2-Mpro) coded by its nsp5 gene …
Synthesis and Preliminary Anti-Inflammatory and Anti-Microbial Evaluation of New 4, 5-Dihydro-1H-Pyrazole Derivatives
S Kanaan, TNA Omar - … Sciences (P-ISSN 1683-3597 E …, 2023 - bijps.uobaghdad.edu.iq
Organic compounds with pyrazole cores have a variety of uses, notably in the
pharmaceutical and agrochemical sectors. The interest in creating pyrazole compounds …
pharmaceutical and agrochemical sectors. The interest in creating pyrazole compounds …
[PDF][PDF] POUR LE DIPLOME D'ETAT DE DOCTEUR EN PHARMACIE
MB Lucile - 2023 - pepite-depot.univ-lille.fr
Les coronavirus sont une vaste famille de virus à ARN capables d'infecter de nombreuses
espèces d'oiseaux et de mammifères, dont l'Homme. Au total, sept coronavirus peuvent …
espèces d'oiseaux et de mammifères, dont l'Homme. Au total, sept coronavirus peuvent …